These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. HIV drug resistance tendencies in Latvia. Kolupajeva T; Aldins P; Guseva L; Dusacka D; Sondore V; Viksna L; Rozentale B Cent Eur J Public Health; 2008 Sep; 16(3):138-40. PubMed ID: 18935781 [TBL] [Abstract][Full Text] [Related]
6. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings. Hill A; McBride A; Sawyer AW; Clumeck N; Gupta RK J Infect Dis; 2013 Jun; 207 Suppl 2():S78-84. PubMed ID: 23687293 [TBL] [Abstract][Full Text] [Related]
7. [Drug resistance mutations and its associated factors among 579 HIV/AIDS patients experiencing failure of antiretroviral therapy in Jiangsu Province, China]. Xiao PP; Lu J; Hu HY; Xu XQ; Ding P; Fu GF; Huan XP; Zhou Y; Yang HT Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Nov; 51(11):988-993. PubMed ID: 29136743 [No Abstract] [Full Text] [Related]
8. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group. Puig T; Pérez-Olmeda M; Rubio A; Ruiz L; Briones C; Franco JM; Gómez-Cano M; Stuyver L; Zamora L; Alvarez C; Leal M; Clotet B; Soriano V AIDS; 2000 Apr; 14(6):727-32. PubMed ID: 10807196 [TBL] [Abstract][Full Text] [Related]
9. [Analysis of HIV-1 drug resistance among 1 922 individuals experiencing virological failure of first-line antiretroviral therapy in Henan province]. Liu J; Yan J; Yang W; Xue X; Sun G; Liu C; Tian S; Sun D; Zhu Q; Wang Z Zhonghua Yu Fang Yi Xue Za Zhi; 2015 Nov; 49(11):950-5. PubMed ID: 26833003 [TBL] [Abstract][Full Text] [Related]
10. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005]. Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780 [TBL] [Abstract][Full Text] [Related]
11. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens. Joly V; Descamps D; Yeni P AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447 [TBL] [Abstract][Full Text] [Related]
12. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ; Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704 [TBL] [Abstract][Full Text] [Related]
13. High rate of antiretroviral drug resistance mutations in HIV type 1-infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. Kebe K; Thiam M; Diagne Gueye NR; Diop H; Dia A; Signate Sy H; Charpentier C; Belec L; Mboup S; Toure Kane C AIDS Res Hum Retroviruses; 2013 Feb; 29(2):242-9. PubMed ID: 22860571 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of HIV drug resistance mutation in the northern Indian population after failure of the first line antiretroviral therapy. Sinha S; Shekhar RC; Ahmad H; Kumar N; Samantaray JC; Sreenivas V; Khan NH; Mitsuyasu RT Curr HIV Res; 2012 Sep; 10(6):532-8. PubMed ID: 22716105 [TBL] [Abstract][Full Text] [Related]
15. Antiretroviral resistance in viral isolates from HIV-1-transmitting mothers and their infants. Bauer GR; Colgrove RC; Larussa PS; Pitt J; Welles SL AIDS; 2006 Aug; 20(13):1707-12. PubMed ID: 16931934 [TBL] [Abstract][Full Text] [Related]
16. Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019-2021. Viñuela L; de Salazar A; Fuentes A; Serrano-Conde E; Falces-Romero I; Pinto A; Portilla I; Masiá M; Peraire J; Gómez-Sirvent JL; Sanchiz M; Iborra A; Baza B; Aguilera A; Olalla J; Espinosa N; Iribarren JA; Martínez-Velasco M; Imaz A; Montero M; Rivero M; Suarez-García I; Maciá MD; Galán JC; Perez-Elias MJ; García-Fraile LJ; Moreno C; Garcia F J Med Virol; 2023 Dec; 95(12):e29287. PubMed ID: 38084763 [TBL] [Abstract][Full Text] [Related]
17. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. Salomon H; Wainberg MA; Brenner B; Quan Y; Rouleau D; Coté P; LeBlanc R; Lefebvre E; Spira B; Tsoukas C; Sekaly RP; Conway B; Mayers D; Routy JP AIDS; 2000 Jan; 14(2):F17-23. PubMed ID: 10708278 [TBL] [Abstract][Full Text] [Related]
18. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children. Delaugerre C; Warszawski J; Chaix ML; Veber F; Macassa E; Buseyne F; Rouzioux C; Blanche S J Med Virol; 2007 Sep; 79(9):1261-9. PubMed ID: 17607781 [TBL] [Abstract][Full Text] [Related]
19. Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States. Ross LL; Shortino D; Shaefer MS AIDS Res Hum Retroviruses; 2018 Aug; 34(8):672-679. PubMed ID: 29732898 [TBL] [Abstract][Full Text] [Related]
20. HIV-1 Drug Resistance Profiles for the HIV Protease and Reverse Transcriptase Gene in Patients Receiving Combination Therapy in Tehran, Iran. Sadeghi L; Lolaie M; Tabatabai RA; Bayanolhagh S; Taj L; Ahmadi NE; Abedinzadeh N; Vakili F; Ahmadi G; Mohraz M Infect Disord Drug Targets; 2018; 18(3):241-248. PubMed ID: 29663899 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]